

0040-4039(94)01504-X

## Predictive Models for the Overall 5-*endo*-trig Iodocyclisation of Homoallylic Alcohols

Jenny M. Barks and David W. Knight\*


Department of Chemistry, University Park, Nottingham, NG7 2RD, UK.

Christopher J. Seaman and Gordon G. Weingarten


Glaxo Research and Development Ltd., Greenford Road, Greenford, Middlesex, UB6 0HE, UK

**Abstract:** - Iodoetherifications of all isomers of the 3-methylalk-4-en-2-ols [14-17] proceed with excellent levels of stereoselectivity, leading to tetrasubstituted tetrahydrofurans [18-22], via overall *anti*-addition to the alkene function.

The intramolecular iodoetherification of 4-penten-1-ol functions, an overall 5-*exo*-trig process, constitutes an efficient, generally applicable and often highly stereoselective approach to tetrahydrofurans which is applicable to a wide range of substitution patterns.<sup>1</sup> We have recently reported that related iodoetherifications of the homoallylic alcohols [1 and 3; R<sup>1</sup>, R<sup>2</sup> = alkyl, silyloxyalkyl], formally *via* a 5-*endo*-trig pathway, can also be very effective in the stereocontrolled elaboration of 2,5-*trans*-(2) or 2,5-*cis*-(4)-tetrahydrofurans;<sup>2</sup> a crucial feature of these cyclisations is the use of anhydrous acetonitrile as solvent.



There have been only a limited number of reports of this type of cyclisation until recently. The first appears to have been an isolated example reported briefly by Bartlett and Myerson;<sup>3</sup> given a choice, 5-*exo* cyclisations always take preference<sup>4</sup> and even 4-*exo* ring closures can compete successfully.<sup>5</sup> Similar results to ours, but using mainly homoallylic alcohols having heteroaryl substituents at the distal end as substrates, have also been reported by a Korean group.<sup>6</sup> In seeking ways to extend the utility of this type of cyclisation, we have recently shown that such cyclisations can also be applied to the stereoselective elaboration of annulated tetrahydrofurans [eg. 6] by cyclisations of 2-alkenylcycloalkan-1-ols [eg. 5].<sup>7</sup>




All of these results involve the overall *anti* addition of iodine and the hydroxyl group across the double bond of the homoallylic alcohol. We were therefore attracted by the possibility of using this type of cyclisation to prepare a variety of tetrasubstituted tetrahydrofurans in a highly stereocontrolled manner by starting with more




Similar treatment of the *anti*-(E)-isomer **15** also gave, after 3h at 0°C, a single iodotetrahydrofuran **19** in 81% yield,<sup>11,12</sup> the identity of which was established exactly as in the foregoing example.

Cyclisations of the corresponding *syn* diastereoisomers [**16** and **17**] using the I<sub>2</sub>-NaHCO<sub>3</sub>-MeCN method proved to be equally facile and efficient but slightly less stereoselective. Conversion of the *syn*-(Z)-alkenol **16** was complete after ~4h at 0°C and gave the iodo-THF **20**, contaminated with some 5% of the THF **21**, which probably arose by *in situ* isomerization of the (Z)-alkene, in a combined yield of >95%.<sup>11,12</sup> The corresponding *syn*-(E)-alkenol **17** however gave a mixture of two, separable iodoTHFs in a ratio of 9:1 [0°C, 1h], which were assigned the structures shown [**21** and **22**], again from NMR data, as outlined above.<sup>11,12</sup>




The <sup>1</sup>H and <sup>13</sup>C NMR data (CDCl<sub>3</sub>), the latter in parentheses, presented with the structures [**18**-**22**] shows an encouraging level of internal consistency. For example, a 2,3-*trans* relationship between the butyl chain and the iodine atom [**19**, **21**] results in 2-CH(O) resonances at δ<sub>H</sub> ~4.1 and δ<sub>C</sub> ~86 ppm, CHI resonances at δ<sub>H</sub> ~3.4 and δ<sub>C</sub> ~34 ppm and the side-chain CH<sub>2</sub> group at δ<sub>C</sub> ~32 ppm, clearly distinguishable from the corresponding resonances for the 2,3-*cis* isomers **18** and **20**. Similar relationships apply to the remainder of the data.



We also briefly examined the use of *N*-iodosuccinimide [NIS] as an alternative source of iodine for these cyclisations. In general, using dichloromethane as solvent at 20°C, the reactions were much slower (up to 24h for completion) than with I<sub>2</sub>-NaHCO<sub>3</sub>-MeCN; even so, cyclisations of the (Z)- and (E)-*anti*-alkenols [**14** and **15**] gave the same products [**18** and **19** respectively] in similar yields and stereospecificities. Unexpectedly, reaction between NIS and the *syn*-(Z)-alkenol **16** led to a 3:1 mixture of the expected iodoTHF **20** and the iodo-oxetane **23** in a combined yield of 50%. This is the first time that we have observed an oxetane in such cyclisations; the stereochemistry has been tentatively assigned from coupling constant and NOE data. By contrast, reaction between the *syn*-(E)-alkenol **17** and NIS gave the same mixture of iodoTHFs [**21** and **22**] as did iodine, but with reduced selectivity [6:1].

The excellent level of stereoselection in the cyclisations of the *anti*-alkenols **14** and **15** are consistent with the involvement of the transition state geometries **24** and **25** respectively, in which both substituent methyl groups are positioned pseudoequatorially. Cyclisations of the related *syn*-isomers **16** and **17** can be rationalized on the basis of the geometries **26** and **27** wherein there is a distinct preference for the substituent adjacent to the hydroxyl group to be positioned pseudoaxially with the remaining β-Me group in a pseudoequatorial position, resulting in a final positioning of the iodine *trans* to the two substituent methyls. These models should have predictive value in the design of syntheses using this cyclisation method. Finally, we suggest that the results [eg. **7** → **8**] reported by Lipshutz and Barton are incorrect,<sup>8,9,13</sup> as all of the foregoing cyclisations appear to

proceed by *anti* addition to the alkene function.



### Acknowledgements

We are grateful to Dr P. Kocovsky (Leicester University) for helpful comments and to Glaxo Research and Development Ltd and the SERC for financial support (CASE Award).

### References

- For reviews, see Boivin, T. L. B. *Tetrahedron*, 1987, **43**, 3309; Harmange, J.-C.; Figadere, B. *Tetrahedron:Asymmetry*, 1993, **4**, 1711.
- Bennett, F.; Bedford, S. B.; Bell, K. E.; Fenton, G.; Knight, D. W.; Shaw, D. *Tetrahedron Lett.*, 1992, **33**, 6507; Bedford, S. B.; Bell, K. E.; Fenton, G.; Hayes, C. J.; Knight, D. W.; Shaw, D. *Tetrahedron Lett.*, 1992, **33**, 6511.
- Bartlett, P. A.; Myerson, J. *J. Am. Chem. Soc.*, 1978, **100**, 3950.
- See, for example, Williams, D. R.; Grote, J.; Harigaya, Y. *Tetrahedron Lett.*, 1984, **25**, 5231; Williams, D. R.; White, F. H. *Tetrahedron Lett.*, 1986, **27**, 2195; Reitz, A. B.; Nortey, S. O.; Maryanoff, B. E. *Tetrahedron Lett.*, 1985, **26**, 3915; Marek, I.; Lefrançois, J.-M.; Normant, J.-F. *Tetrahedron Lett.*, 1992, **33**, 1747. See also Dehmlow, H.; Mulzer, J.; Seilz, C.; Strecker, A. R.; Kohlmann, A. *Tetrahedron Lett.*, 1992, **33**, 3607.
- Srebniak, M.; Mechoulam, R. *J. Chem. Soc., Chem. Commun.*, 1984, 1070; Evans, R. D.; Magee, J. W.; Schauble, J. H. *Synthesis*, 1988, 862. See also Takano, S.; Sekiguchi, Y.; Shimazaki, Y.; Ogasawara, K. *Tetrahedron Lett.*, 1989, **30**, 4001.
- Kang, S. H.; Lee, S. B. *Tetrahedron Lett.*, 1993, **34**, 1955; Kang, S. H.; Lee, S. B. *Tetrahedron Lett.*, 1993, **34**, 7579.
- Barks, J. M.; Knight, D. W.; Weingarten, G. G. *J. Chem. Soc., Chem. Commun.*, 1994, 719.
- Lipshutz, B. H.; Barton, J. C. *J. Am. Chem. Soc.*, 1992, **114**, 1084.
- Mihelich, E. D.; Hite, G. A. *J. Am. Chem. Soc.*, 1992, **114**, 7318.
- Yamaguchi, M.; Hirao, I. *Tetrahedron Lett.*, 1983, **24**, 391.
- Yields refer to isolated products which showed correct spectroscopic and analytical data, with the exception of THF **22**, which was not cleanly separated; hence the approximations in some of the NMR data for **22**.
- NOE data (%) [numbering system: BuCH(2); CIH(3) etc.]:- **19** H(2)-H(4), 3; H(2)-Me(5), 1.5; H(2)-H(3,5), <1; H(3)-H(5), 2.5; H(3)-Me(4), 5; H(3)-H(4), <1; H(4)-H(5), <1; H(4)-Me(5) 4.5; H(5)-Me(4), 7; **20** H(2)-H(3), 8.5; H(2)-H(4), ~0; H(2)-H(5), <1; H(2)-Me(4), 5.5; H(2)-Me(5), 1; H(3)-H(4), 1; H(3)-H(5), ~0; H(3)-Me(4), 4; H(3)-Me(5), 1.5; H(4)-H(5), 6; H(4)-Me(5), ~0; H(5)-Me(4), ~0; **21** H(2)-H(3), <1; H(2)-H(4), 6; H(2)-H(5), 1; H(2)-Me(4), ~0; H(2)-Me(5), ~0; H(3)-H(4), 1; H(3)-H(5), ~0; H(3)-Me(4), 7.5; H(3)-Me(5), 2.5; H(4)-H(5), 7.5; Me(4)-H(2,5), ~0.
- Correspondence with Professor Lipshutz has confirmed that he has reached the same conclusions; we are grateful for his helpful comments on our own work.

(Received in UK 7 June 1994; revised 29 July 1994; accepted 4 August 1994)